Navigation Links
Encorium Reports Second Quarter 2009 Financial Results
Date:8/24/2009

dditional capital and continued listing of our common stock on Nasdaq. You should not place undue reliance on any forward-looking statement. We undertake no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances after the date they are made or to reflect the occurrence of unanticipated events. Please refer to the section entitled "Risk Factors" in the Company Annual Report on Form 10-K for the year ended December 31, 2008 and the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2009 for a more complete discussion of factors which could cause our actual results and financial position to change.

You should not place any undue reliance on these forward-looking statements which speak only as of the date of this press release. Additional information concerning factors that might affect our business or stock price which could cause actual results to materially differ from those in forward-looking statements is contained in Encorium Group's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2008 and other periodic reports under the Securities Exchange Act of 1934, as amended, copies of which are available upon request from Encorium Group's investor relations department.



                                ENCORIUM GROUP, INC
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                    (UNAUDITED)

                        Three Months              Six Months
                            Ended                    Ended
                           June 30,                 June 30,
                             2009        2008         2009         2008

        Net revenue     $4,483,263   $5,917,591   $9,021,436  $11,320,070
        Reimbursement
         revenue           799,315    1,059,297    1,915,366    1,968,736
    Total Revenue        5,282,578    6,976,888   10,936
'/>"/>
SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
2. Encorium Reports Third Quarter 2008 Financial Results
3. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
4. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
5. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
6. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
7. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
8. Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
9. Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
10. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
11. QMed, Inc. Reports July Medicare SNP Enrollments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy & ... it has signed a letter of intent to ... developed and patented a nanotechnology-based development platform used ... that enable rapid on-site collection and testing to ... health issues in an immediate, non-invasive and cost-effective ...
(Date:12/22/2014)... December 22, 2014 The ... publication of original research, reviews and editorials addressing ... clinical practice, today published a provocative article exploring ... development, progression and potential treatment of prostate cancer. ... research and proposes the possibility that there could ...
(Date:12/19/2014)... and Hershey, PA (PRWEB) December 19, 2014 ... BJCT), a leading developer and manufacturer of needle-free ... into an agreement with Immunomic Therapeutics, Inc. (“ITI”) ... needle-free injection device with its LAMP™ vaccine platform. ... option for an exclusive Worldwide license to the ...
(Date:12/19/2014)... Ill. , Dec. 19, 2014 Naurex ... develop novel drugs for diseases of the central nervous ... president and chief executive officer, will present at the ... Riedel,s presentation will take place at 3:00 p.m. PST ... Francis in San Francisco, Calif. ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... , ATLANTA and LONDON, Sept. 10 ... biological medical device and cardiovascular tissue processing company, today announced the ... Matrix, which received CE mark approval in August 2009. BioFoam was ... supplemental measure to promote hemostasis (a complex process that stops bleeding) ...
... WATERTOWN, Mass., Sept. 10 Tetraphase Pharmaceuticals ... technology announced today that it will present three (3) ... and antibacterial activity of analogs from several novel classes ... Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in ...
... BALTIMORE, Sept. 10 Champions Biotechnology, Inc. ... oncology services division assists physicians by providing personalized treatment options ... with PinnacleCare , the pioneer and the ... , PinnacleCare will offer Champions, personalized oncology services ...
Cached Biology Technology:CryoLife Announces First Clinical Use of BioFoam(R) 2CryoLife Announces First Clinical Use of BioFoam(R) 3CryoLife Announces First Clinical Use of BioFoam(R) 4CryoLife Announces First Clinical Use of BioFoam(R) 5Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009 2Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 2Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 3Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 4
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ... technology is accurate, flexible and robust – with the ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) ... Market in the APAC Region 2015-2019"  report to ... emerging in this market is advances in technology. ... to upgrade biometric solutions to the latest standard ...
(Date:12/10/2014)... You,ve been here before: you desperately need to sign into ... key or the answer to your secret question. What,s your ... Today, Hoyos Labs , a digital infrastructure security ... an end to the frustration that comes with usernames, passwords ... a user,s smartphone to acquire his or her biometrics to ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... July 23, 2013 The goal of smart cities ... performance, efficiency and functionality. This is expressed through an ... of the overall city experience.  Cities are hoping to ... city projects to ultimately drive economic growth. Some key ...
... in the July issue of the Journal of ... super-infections like pneumonia with influenza. The research was led ... infectious disease specialist who is also chair of the ... Science Center and adjunct faculty at St. Jude Children,s ...
... NY. -- The use of central nervous system fetal ... cells for transplantation procedures aimed at restoring damage done ... tissue microbial contaminants have been known to cause brain ... team from Germany has developed a "washing" technique that ...
Cached Biology News:Frost & Sullivan: Moving the Smart Cities Idea from Concept to Reality 2Frost & Sullivan: Moving the Smart Cities Idea from Concept to Reality 3Frost & Sullivan: Moving the Smart Cities Idea from Concept to Reality 4Frost & Sullivan: Moving the Smart Cities Idea from Concept to Reality 5New protocol developed to decontaminate human fetal tissues used for cell transplantation 2
... for the rapid purification of linear 100 bp ... DNA band is excised from an,agarose gel and ... base of the column are a series of ... back while allowing DNA to selectively pass through ...
... is Tecans state-of-the-art software for all your ... scheduling in a single, scalable software package. ... consistent, simplifying the control of all Freedom ... Freedom EVO 100 with one liquid handling ...
...
... Isolation Kit provides all the reagents ... vesicle fraction. The isolation procedure involves ... synaptosomes, and differential centrifugation followed by ... also contains an antibody specific for ...
Biology Products: